Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Brian Corvese Insider Profile
4 Followers
Brian Corvese, Director at Agenus, holds 383.49K shares in MiNK Therapeutics (Ticker: INKT), holds 92.08K shares in Agenus (Ticker: AGEN), holds ― shares in Protagenic Therapeutics (Ticker: PTIX).
Brian Corvese has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Brian Corvese holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Brian Corvese
Brian Corvese's Trading History
Agenus
Jun 21, 2021
Director
Uninformative Buy
112.36K
$1.63M
MiNK Therapeutics
Jun 05, 2024
Director
Uninformative Buy
17.79K
$398.45K
Protagenic Therapeutics
―
Director
―
―
List of latest transactions for each holding click on a transaction to see Brian Corvese's performance on stock
You May Also Like
Brian Corvese insider profile FAQ
What is the percentage of profitable transactions made by Brian Corvese?
The percentage of profitable transactions made by Brian Corvese is ―.
What is the average return per transaction made by Brian Corvese?
The average return per transaction made by Brian Corvese is ―.
What stocks does Brian Corvese hold?
Brian Corvese holds: AGEN, INKT, PTIX stocks.
What was Brian Corvese’s latest transaction?
Brian Corvese latest transaction was an Uninformative Buy of $17.79K.
What was Brian Corvese's most profitable transaction?
Brian Corvese’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Brian Corvese's role in Agenus?
Brian Corvese's role in Agenus is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.